The future of vitamin D analogs
Open Access
- 3 April 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 5, 122
Abstract
The active form of vitamin D3, 1,25-dihydroxyvitamin D3, is a major regulator of bone and calcium homeostasis. In addition, this hormone also inhibits the proliferation and stimulates the differentiation of normal as well as malignant cells. Supraphysiological doses of 1,25-dihydroxyvitamin D3 are required to reduce cancer cell proliferation. However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin D3 have been synthesized by the introduction of chemical modifications in the A-ring, central CD-ring region or side chain of 1,25-dihydroxyvitamin D3 in the hope to find molecules with a clear dissociation between the beneficial antiproliferative effects and adverse calcemic side effects. One example of such an analog with a good dissociation ratio is calcipotriol (DaivonexR), which is clinically used to treat the hyperproliferative skin disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used in the clinic for the treatment of cancer although several analogs have been shown to be potent drugs in animal models of cancer. Omics studies as well as in vitro cell biological experiments unraveled basic mechanisms involved in the antineoplastic effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D3 and analogs act in a cell type- and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 towards S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of tumor cells together with effects on angiogenesis and inflammation have been implicated in the pleiotropic effects of 1,25-dihydroxyvitamin D3 and its analogs. In this review we will give an overview of the action of vitamin D analogs in tumor cells and look forward how these compounds could be introduced in the clinical practice.Keywords
This publication has 111 references indexed in Scilit:
- Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosisJournal of Bone and Mineral Metabolism, 2012
- Inecalcitol, an analog of 1α,25(OH)2D3, induces growth arrest of androgen‐dependent prostate cancer cellsInternational Journal of Cancer, 2011
- Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in ratsCardiovascular Research, 2011
- A Novel Gemini Vitamin D Analog Represses the Expression of a Stem Cell Marker CD44 in Breast CancerMolecular Pharmacology, 2011
- A Vitamin D Receptor-Alkylating Derivative of 1α,25-Dihydroxyvitamin D3 Inhibits Growth of Human Kidney Cancer Cells and Suppresses Tumor GrowthCancer Prevention Research, 2010
- Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitolJournal of Cellular Biochemistry, 2010
- Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signalingThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- EB1089 inhibits the parathyroid hormone–related protein–enhanced bone metastasis and xenograft growth of human prostate cancer cellsMolecular Cancer Therapeutics, 2009
- Gemini Vitamin D Analogues Inhibit Estrogen Receptor–Positive and Estrogen Receptor–Negative Mammary Tumorigenesis without Hypercalcemic ToxicityCancer Prevention Research, 2008
- 1,25-DIHYDROXYVITAMIN D3AND MALIGNANT MELANOMA: THE PRESENCE OF RECEPTORS AND INHIBITION OF CELL GROWTH IN CULTUREEndocrinology, 1981